UP!

MDVN $81.44

MDVN target price
81.44
0
0
Medivation, Inc.
Industry Pharmaceutical industry
Founded 2004
Headquarters San Francisco, California, United States
Owner Pfizer
Website medivation.com

Medivation is an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation, in collaboration with Astellas, is currently developing enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI® (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor. Medivation is headquartered in San Francisco, California, and it began operations in December 2004 with the acquisition of Medivation Neurology, Inc. The current CEO is David Hung.

Pfizer announced it would acquire the company in August 2016, and completed the acquisition the following month.

On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares. In response, a security fraud class-action lawsuit was initiatied by Izard Nobel LLP, alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer's disease.

The counsel for the case was Bernstein Liebhard and the lead plaintiffs were initially David Applestein then Catoosa Fund, LP. On March 22, 2012, the case was dismissed with prejudice. The plaintiffs appealed the dismissal in the Ninth Circuit Court of Appeals. The Ninth Circuit granted oral argument which will be held on Friday, January 17, 2014. On March 7, 2014, the Ninth Circuit affirmed the dismissal of the class action, Catoosa Fund LP v. Medivation, Inc., No. 12-15960. The Ninth Circuit stated "With the exception of the tenuous and unattributed statement that Dr. Schneider relates secondhand, plaintiff has not pled any facts supporting an inference of actual knowledge by defendants. Plaintiff relies heavily on the inference that, due to their positions, the defendants must have known about the unmatched nature of the study. That inference is entirely speculative and does not rise to the required strong inference; plaintiff's allegation is not at least as compelling as any opposing inference one could draw from the facts alleged."

In April the company was linked with a number of potential acquirers including Roche, AstraZeneca, Amgen and Gilead Sciences, and a possible hostile bid from Sanofi. AstraZeneca was reported to weigh in with an offer of £7 billion ($10 billion). On April 29, Sanofi launched a $9.3 billion takeover offer which was rejected by the Medivation board. In August, Pfizer announced that it would acquire the company for $14 billion or $81.50 per share, a 21% premium over the closing price on August 19; the acquisition was completed September 28.

EY Entrepreneur of the Year 2014 National Winner.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-07-12 Reiterated Rating Credit Suisse Group AG Buy $63.00
2016-07-12 Reiterated Rating Wedbush Outperform $63.00 to $66.00
2016-07-07 Reiterated Rating BMO Capital Markets Market Perform $50.00
2016-07-07 Reiterated Rating Leerink Swann Market Perform $64.00
2016-07-07 Reiterated Rating Jefferies Group Hold $56.00
2016-07-06 Reiterated Rating Credit Suisse Group AG Outperform $63.00
2016-06-30 Reiterated Rating Leerink Swann Hold
2016-06-26 Reiterated Rating Citigroup Inc. Buy
2016-06-16 Reiterated Rating Barclays Overweight $70.00
2016-06-16 Reiterated Rating Barclays PLC Overweight $70.00
2016-06-08 Reiterated Rating Credit Suisse Buy
2016-06-08 Reiterated Rating Credit Suisse Group AG Buy
2016-05-09 Reiterated Rating BMO Capital Markets Market Perform $47.00 to $50.00
2016-05-09 Reiterated Rating Jefferies Group Hold $52.00 to $56.00
2016-05-08 Reiterated Rating Credit Suisse Buy
2016-05-08 Reiterated Rating Barclays Buy
2016-05-07 Reiterated Rating Leerink Swann Market Perform $39.00 to $64.00
2016-05-07 Reiterated Rating RBC Capital Sector Perform $40.00 to $70.00
2016-05-07 Reiterated Rating Brean Capital Buy $61.00
2016-05-07 Reiterated Rating Royal Bank Of Canada Sector Perform $40.00 to $70.00
2016-05-06 Boost Price Target Barclays Overweight $48.00 to $70.00
2016-05-06 Upgrade Citigroup Inc. Neutral to Buy $37.00 to $73.00
2016-05-05 Boost Price Target Maxim Group Buy $47.00 to $76.00
2016-05-04 Downgrade Mizuho Neutral to Underperform $150.00
2016-05-03 Boost Price Target Credit Suisse $63.00
2016-05-02 Boost Price Target Jefferies Group Hold $39.00 to $52.00
2016-05-02 Boost Price Target Stifel Nicolaus Buy $52.00 to $66.00
2016-05-01 Reiterated Rating Credit Suisse Outperform $49.00
2016-05-01 Reiterated Rating Goldman Sachs Neutral $44.00
2016-05-01 Reiterated Rating Goldman Sachs Group Inc. Neutral $44.00
2016-04-30 Reiterated Rating Wedbush Buy
2016-04-29 Boost Price Target Wedbush Outperform $47.00 to $59.00
2016-04-28 Reiterated Rating Citigroup Inc. Hold $37.00
2016-04-25 Reiterated Rating Leerink Swann Hold $55.00 to $70.00
2016-04-19 Reiterated Rating SunTrust Buy $56.00
2016-04-19 Upgrade Canaccord Genuity Hold to Buy $45.00 to $70.00
2016-04-19 Reiterated Rating SunTrust Banks Inc. Buy $56.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-04-11 Initiated Coverage BMO Capital Markets Market Perform $47.00
2016-04-10 Reiterated Rating Leerink Swann Market Perform
2016-04-06 Reiterated Rating Canaccord Genuity Hold
2016-04-05 Initiated Coverage SunTrust Buy $56.00
2016-04-04 Reiterated Rating BTIG Research Hold
2016-04-02 Reiterated Rating Credit Suisse Buy
2016-04-01 Reiterated Rating Jefferies Group Hold $39.00
2016-03-31 Boost Price Target Credit Suisse Outperform $48.00 to $49.00
2016-03-31 Reiterated Rating Leerink Swann Hold $39.00
2016-03-30 Reiterated Rating Barclays Buy $42.57
2016-03-30 Initiated Coverage Goldman Sachs Neutral $44.00
2016-03-29 Reiterated Rating Canaccord Genuity Hold $45.00
2016-03-28 Boost Price Target Barclays Overweight $45.00 to $48.00
2016-03-22 Downgrade Canaccord Genuity Hold $45.00
2016-03-07 Reiterated Rating Maxim Group Buy $47.00
2016-02-26 Reiterated Rating Canaccord Genuity Hold $45.00
2016-02-26 Reiterated Rating Brean Capital Buy $61.00
2016-02-26 Reiterated Rating Leerink Swann Market Perform $41.00 to $39.00
2016-02-19 Lower Price Target Citigroup Inc. $40.00 to $35.00
2016-02-19 Initiated Coverage Bank of America Buy $45.00
2016-02-19 Initiated Coverage Bank of America Corp. Buy $45.00
2016-02-06 Reiterated Rating Leerink Swann Hold
2016-02-04 Initiated Coverage Leerink Swann Market Perform $41.00
2016-02-02 Reiterated Rating Maxim Group Buy $47.00
2016-02-01 Lower Price Target Wedbush Outperform $59.00 to $47.00
2016-01-31 Reiterated Rating Credit Suisse Buy
2016-01-31 Reiterated Rating William Blair Outperform $83.00
2016-01-28 Reiterated Rating Stifel Nicolaus Buy
2016-01-27 Downgrade Canaccord Genuity Buy to Hold $90.00 to $45.00
2016-01-26 Reiterated Rating Maxim Group Buy $54.00
2016-01-20 Initiated Coverage Credit Suisse Outperform
2016-01-19 Lower Price Target Brean Capital Buy $71.00 to $61.00
2015-11-10 Lower Price Target Maxim Group Buy $74.00 to $54.00
2015-11-07 Reiterated Rating RBC Capital Hold
2015-11-06 Lower Price Target RBC Capital Sector Perform $50.00 to $40.00
2015-11-06 Lower Price Target Barclays Overweight $75.00 to $65.00
2015-10-30 Reiterated Rating Wedbush Outperform $69.00 to $63.00
2015-10-27 Reiterated Rating Jefferies Group Hold $59.00 to $50.00
2015-10-26 Lower Price Target JMP Securities Market Outperform $152.00 to $75.00
2015-10-09 Reiterated Rating Canaccord Genuity Buy
2015-09-30 Upgrade Cowen and Company Underperform to Market Perform
2015-09-28 Reiterated Rating RBC Capital Sector Perform
2015-09-28 Reiterated Rating Maxim Group Buy $171.00 to $74.00
2015-09-17 Set Price Target William Blair $83.00
2015-09-15 Initiated Coverage Nomura Buy $140.00
2015-09-15 Initiated Coverage Nomura Holdings Inc. Buy $140.00
2015-09-03 Initiated Coverage Citigroup Inc. Neutral
2015-08-27 Boost Price Target William Blair Outperform $152.00 to $166.00
2015-08-27 Reiterated Rating Stifel Nicolaus Buy $114.00
2015-08-26 Reiterated Rating Maxim Group Buy $171.00
2015-08-25 Reiterated Rating Brean Capital Buy $142.00
2015-08-25 Reiterated Rating BTIG Research Hold
2015-08-10 Reiterated Rating Jefferies Group Hold $118.00
2015-08-10 Reiterated Rating Brean Capital Buy $142.00
2015-08-10 Reiterated Rating Canaccord Genuity Buy $180.00
2015-08-07 Boost Price Target JMP Securities Market Outperform $143.00 to $152.00
2015-08-07 Boost Price Target Cowen and Company Underperform $77.00 to $80.00
2015-07-30 Lower Price Target Stifel Nicolaus Buy $146.00 to $107.00
2015-07-29 Lower Price Target Cowen and Company Underperform $84.00 to $77.00
2015-07-13 Initiated Coverage BTIG Research Hold
2015-06-04 Boost Price Target Maxim Group Buy $155.00 to $168.00
2015-06-02 Set Price Target Brean Capital Buy $142.00
2015-05-18 Reiterated Rating RBC Capital Sector Perform
2015-05-11 Reiterated Rating Citigroup Inc. Buy $147.00 to $145.00
2015-05-11 Reiterated Rating JMP Securities Outperform $143.00
2015-05-08 Boost Price Target Maxim Group Buy $126.00 to $155.00
2015-05-05 Set Price Target Canaccord Genuity Buy $180.00
2015-04-20 Reiterated Rating Credit Suisse Outperform to Neutral $98.00 to $115.00
2015-04-10 Boost Price Target Canaccord Genuity Buy $132.00 to $180.00
2015-04-02 Set Price Target Canaccord Genuity Buy $132.00 to $180.00
2015-03-31 Upgrade Jefferies Group Hold $136.00
2015-03-30 Boost Price Target Maxim Group Buy $126.00 to $163.00
2015-03-27 Boost Price Target Barclays Overweight $133.00 to $150.00
2015-03-25 Boost Price Target JMP Securities Market Outperform $126.00 to $143.00
2015-03-25 Boost Price Target JPMorgan Chase & Co. Overweight $130.00 to $148.00
2015-03-25 Boost Price Target Brean Capital Buy $125.00 to $142.00
2015-03-11 Boost Price Target Wedbush Outperform $118.00 to $138.00
2015-03-02 Boost Price Target Maxim Group Buy $118.00 to $126.00
2015-03-01 Reiterated Rating Canaccord Genuity Buy $132.00
2015-02-27 Reiterated Rating Citigroup Inc. Buy $122.00 to $147.00
2015-02-26 Boost Price Target Brean Capital Buy $118.00 to $125.00
2015-02-26 Boost Price Target JPMorgan Chase & Co. Overweight $117.00 to $130.00
2015-02-26 Boost Price Target Barclays Overweight $130.00 to $133.00
2015-01-29 Boost Price Target Stifel Nicolaus Buy $112.00 to $128.00
2015-01-22 Reiterated Rating Brean Capital Buy $118.00
2015-01-22 Initiated Coverage RBC Capital Sector Perform $100.00
2015-01-06 Initiated Coverage Barclays Overweight $130.00
2014-12-24 Set Price Target William Blair Buy $116.00
2014-11-07 Reiterated Rating Citigroup Inc. Buy $116.00 to $122.00
2014-11-07 Reiterated Rating Brean Capital Buy $105.00 to $118.00
2014-10-07 Initiated Coverage JMP Securities Outperform $122.00
2014-09-24 Downgrade Goldman Sachs Buy to Neutral $90.00 to $110.00
2014-09-18 Upgrade Canaccord Genuity Hold to Buy $60.00 to $132.00
2014-09-15 Reiterated Rating Aegis Buy
2014-09-12 Reiterated Chardan Capital Markets Buy $100 to $122
2014-09-12 Boost Price Target Chardan Capital Buy $100.00 to $122.00
2014-09-11 Boost Price Target Stifel Nicolaus Buy $89.00 to $112.00
2014-09-09 Upgrade Sanford C. Bernstein Market Perform to Outperform $118.00
2014-09-04 Initiated Coverage Credit Suisse Outperform
2014-08-18 Reiterated Rating Jefferies Group Positive
2014-08-08 Boost Price Target Aegis $125.00 to $130.00
2014-08-08 Boost Price Target Leerink Swann $104.00 to $107.00
2014-08-08 Reiterated Rating Keefe, Bruyette & Woods Outperform $104.00 to $107.00
2014-08-08 Boost Price Target Stifel Nicolaus Buy $83.00 to $89.00
2014-08-08 Boost Price Target Brean Capital Buy $100.00 to $105.00
2014-08-04 Boost Price Target Credit Suisse Outperform $95.00 to $98.00
2014-07-02 Reiterated Rating Aegis Buy
2014-06-23 Reiterated Rating Stifel Nicolaus Buy $83.00 to $81.00
2014-06-19 Upgrade Jefferies Group Hold to Buy $80.00
2014-05-22 Initiated Coverage Stifel Nicolaus Buy $81.00
2014-05-09 Reiterated Rating Leerink Swann Outperform $104.00 to $114.00
2014-05-09 Boost Price Target Barclays $62.00 to $65.00
2014-05-06 Reiterated Rating Aegis Positive
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-04-16 Initiated Coverage Canaccord Genuity Hold $60.00
2014-03-17 Boost Price Target Maxim Group Buy $92.00 to $112.00
2014-02-28 Reiterated Rating Maxim Group Buy $84.00 to $92.00
2014-02-28 Reiterated Rating Aegis Buy
2014-02-28 Downgrade Cowen and Company Market Perform to Underperform
2014-02-28 Downgrade Jefferies Group Buy to Hold $89.00 to $80.00
2014-02-03 Reiterated Chardan Capital Markets Buy $100
2014-02-03 Reiterated Rating Chardan Capital Buy $100.00
2014-02-03 Boost Price Target Citigroup Inc. $124.00
2014-02-03 Downgrade Sanford C. Bernstein Outperform to Market Perform $84.00 to $92.00
2014-02-03 Downgrade Needham & Company LLC Buy to Hold $65.00
2014-01-29 Boost Price Target Maxim Group Buy $75.00 to $84.00
2014-01-29 Reiterated Aegis Capital Buy $100 to $125
2014-01-29 Boost Price Target Wedbush $118.00
2014-01-29 Boost Price Target Brean Capital Buy $72.00 to $100.00
2014-01-29 Boost Price Target Aegis Buy $100.00 to $125.00
2014-01-29 Boost Price Target Goldman Sachs $100.00
2014-01-28 Initiated Coverage CRT Capital Buy $88.00
2014-01-27 Boost Price Target Jefferies Group $69.00 to $89.00
2014-01-10 Boost Price Target Barclays Equal Weight $57.00 to $62.00
2013-11-13 Boost Price Target Maxim Group Buy $71.00 to $75.00
2013-11-13 Boost Price Target Barclays Equal Weight $53.00 to $57.00
2013-11-13 Boost Price Target Credit Suisse Outperform $77.00 to $80.00
2013-11-13 Reiterated Rating Aegis Buy
2013-10-28 Reiterated Rating Chardan Capital Buy $72.00
2013-10-28 Boost Price Target Maxim Group Buy $66.00 to $71.00
2013-10-22 Reiterated Rating Aegis Buy
2013-09-18 Initiated Chardan Capital Markets Buy $72
2013-09-18 Initiated Coverage Chardan Capital Buy $72.00
2013-07-17 Upgrade UBS Neutral to Buy $59 to $74
2012-12-19 Initiated UBS Neutral $59
2012-12-04 Initiated Barclays Equal Weight $56
2016-07-12 Reiterated Rating Credit Suisse Group AG Buy $63.00
2016-07-12 Reiterated Rating Wedbush Outperform $63.00 to $66.00
2016-07-07 Reiterated Rating BMO Capital Markets Market Perform $50.00
2016-07-07 Reiterated Rating Leerink Swann Market Perform $64.00
2016-07-07 Reiterated Rating Jefferies Group Hold $56.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Hung David President and CEO 2.02%  (1549189) MDVN / OPXA /
Bailey Gregory 0.90%  (691101) BHVN / MDVN /
Seely Lynn Chief Medical Officer 0.13%  (96694) MDVN /
Machado Clarence Patrick Chief Business Officer and CFO 0.09%  (70792) AAVL / CMRX / ECYT / MDVN / SCYX / TKMR /
Hirmand Mohammad Interim Chief Medical Officer 0.05%  (40239) MDVN /
FALBERG KATHRYN E 0.04%  (32742) ABIO / BMRN / HALO / JAZZ / MDVN /
YARNO WENDY L 0.04%  (32742) ALDR / DRTX / INO / MDVN / PETX / STJ /
Cohen Cheryl Chief Commercial Officer 0.04%  (32436) CYTR / MDVN / TKAI / VTL /
Jarrett Jennifer Chief Financial Officer 0.04%  (29971) ARNA / BOLD / MDVN /
Bierly Rick Chief Financial Officer 0.04%  (28744) IPXL / MDVN /
Powell Andrew Kenneth William SVP, General Counsel & Crp Sec 0.04%  (28517) CRTX / ITMN / MDVN /
Yang Tseli Lily VP, Finance and Accounting 0.03%  (22894) MDVN /
Templeman Thomas SVP, Pharmaceutical Operations 0.03%  (22720) MDVN /
Graham Dawn 0.03%  (21206) ECYT / MDVN / PTCT / XENE /
Kelsey Stephen Michael SVP of New Projects 0.03%  (21000) GERN / MDVN /
Lobacki Joseph M Chief Commercial Officer 0.03%  (19365) CPXX / MDVN / VSTM /
BLICKENSTAFF KIM D 0.02%  (17742) MDVN / TNDM /
VERNON W ANTHONY 0.02%  (17742) KRFT / MDVN / MKC / WWAV /
Rhodes Jennifer J GC & Chief Compliance Officer 0.01%  (11090) ADMS / MDVN /
King Michael L 0.01%  (9090) MDVN /
Adams Daniel 0.01%  (5807) MDVN /